Catalyst

Healthcare providers, we're at @NANOSTweets - North American Neuro-Ophthalmology Society! Do you know how to spot the ophthalmic signs of Lambert-Eaton myasthenic syndrome (LEMS)? Visit the Catalyst table to hear more about symptoms such as ptosis, diplopia, and an FDA-approved treatment for LEMS: lemsawarehcp.com/recognizing-le…

At our inaugural Catalyst Advocacy Scholars Summit (CASS), we turned the spotlight on our scholars at the start of the week, asking what they hoped to discover and what drew them to patient advocacy. Their curiosity, insight, and passion for patient communities were clear from day one. Watch to hear directly from these future healthcare providers and patient advocates as they share their early reflections: ir.catalystpharma.com/news/news-deta…. #CASS2026

When a loved one is diagnosed with a rare disease, caregiving often becomes an integral part of who you are. Bill, a father and caregiver to a son with Duchenne muscular dystrophy (DMD), shares his personal journey of navigating the emotional challenges of this role. Listen to his story on #CatalystConvos: catalystpharma.com/catalyst-convos

Our team attended the 48th Annual Carrell Krusen Neuromuscular Symposium, an immersive clinical education experience designed for multidisciplinary care teams supporting patients with rare and complex neuromuscular conditions. The symposium focuses on disorders such as hereditary muscular dystrophies, motor neuron diseases, neuroimmunologic neuropathies, and rare diseases affecting muscle and nerve, like Lambert-Eaton myasthenic syndrome (LEMS) and Duchenne muscular dystrophy (DMD).

Our President & CEO, Rich Daly, along with other members of our management team, recently participated in the @Barclays 28th Annual Global Healthcare Conference, where we highlighted our exceptional 2025 performance, shared more details around our 2026 guidance, and outlined the growth strategy for our promoted products. Learn more about Catalyst’s 2026 Full Year Financial Guidance: ir.catalystpharma.com/news/news-deta…

Living with Lambert-Eaton myasthenic syndrome (LEMS) and on a Catalyst treatment? The LEMS community is full of people who understand what you're going through. When living with LEMS, finding support is important, and Catalyst Pathways® is here to help. They offer programs for community engagement, financial assistance, and opportunities to connect with other patients who share similar experiences. Connecting with others who understand your journey can make all the difference. Check out Catalyst Pathways® today to learn more about the resources and support available to you. To enroll in Catalyst Pathways® now, please visit: yourcatalystpathways.com

Know your antibodies! Both Lambert-Eaton myasthenic syndrome (LEMS) and myasthenia gravis (MG) are neuromuscular disorders that occur when the body’s own immune system mistakenly attacks itself, which is why these two disorders are frequently confused. Watch and learn more about how a doctor can tell LEMS and MG apart: youtube.com/watch?v=QzwUwE….

Visiting the @MDAorg Clinical & Scientific Conference? Catalyst is here! Visit us at booth #601 to learn more about what we're doing in the DMD (Duchenne muscular dystrophy) community: mdaconference.org This is intended for healthcare providers.

Team Catalyst will be at the 2026 Muscular Dystrophy Association (@MDAorg) Clinical & Scientific Conference. We will showcase real‑world findings in Duchenne muscular dystrophy (DMD) and host a vamorolone-focused symposium, focusing on real-world analysis of vamorolone in patients living with DMD. Learn more about what we are doing in the Duchenne community: ir.catalystpharma.com/news/news-deta…

We’re excited to share our newly optimized website; designed with you in mind. From our history and the diseases we treat, to the communities we proudly serve, everything you’re looking for is now easier to find in one streamlined, easy-to-explore experience. Take a look around: catalystpharma.com.

"Those connections give us the strength to take the next step." In this episode, Mark, a caregiver for his wife who is living with Lambert-Eaton myasthenic syndrome (LEMS), speaks about the pressures that tell men to hide their feelings. He makes a case for why those beliefs must change, sharing from his own experience that vulnerability is not a weakness. Listen here to #CatalystConvos: lnk.to/catalyst-conve…

¡Es el Día de las Enfermedades Raras! Eurordis creó este día para generar conciencia sobre enfermedades raras. También busca mejorar el acceso a diagnóstico, tratamiento, atención y apoyo social para los millones de personas que viven con ellas. En este #RDD2026, queremos compartir una noticia emocionante: hemos sumado más personal de habla hispana a nuestro equipo que sirve a la comunidad de Duchenne, y continuamos fortaleciendo nuestras relaciones con grupos de pacientes hispanohablantes para ayudar a crear más recursos en español. Catalyst sigue comprometido con la comunidad hispanohablante y esperamos continuar colaborando con pacientes, cuidadores y organizaciones de defensa del paciente. - It's Rare Disease Day! This day was created by Eurordis to raise awareness about rare diseases. It also seeks to improve access to diagnosis, treatment, care and social support for the millions of people who live with them. This #RDD2026, we want to share some exciting news: we have added more Spanish-speaking staff to our team serving the Duchenne community, and we continue to strengthen our relationships with Spanish-speaking patient groups to help create more Spanish-language resources. Catalyst remains committed to the Spanish-speaking community and we look forward to continuing to collaborate with patients, caregivers, and advocacy organizations.

In recognition of #RareDiseaseDay on February 28th, we are proud to spotlight the National Organization for @RareDiseases, Inc. (NORD), a leader dedicated to advancing the health, well‑being, and visibility of individuals living with rare diseases. Through their commitment to progress in care, research, and policy, NORD continues to drive meaningful change for the rare disease community. This year, they're inviting everyone to join the movement and #ShowYourStripes to honor the many unique stories and faces that make up the rare disease community. Discover more: rarediseases.org/rare-disease-d…

Catalyst's record fourth quarter and full year 2025 financial results reflect continued commercial strength. Catalyst achieved full year-over-year 2025 revenue growth of 19.8%. With our strong momentum, we project our 2026 total revenue between $615 & $645 million. Catalyst is dedicated to delivering lasting impact for patients and the rare disease community. Learn more: ir.catalystpharma.com/news-releases/…

Catalyst Pharmaceuticals will be participating in the @Barclays 28th Annual Global Healthcare Conference, a healthcare-centered conference that brings together institutional investors, private equity professionals, and senior leadership from hundreds of public and private companies. Our President and CEO, Rich Daly, will be presenting on Tuesday, March 10, 2026, along with other members of our management team: ir.catalystpharma.com/news-releases/….

As we continue preparing for #RareDiseaseDay on February 28th, we are honored to support the EveryLife Foundation for Rare Diseases, an organization that empowers and energizes rare disease advocates to drive meaningful change. Through research, community activation, and a deep commitment to improving health outcomes, EveryLife strengthens the rare disease community and amplifies its collective voice. Discover more about the difference they’re making and how they advocate for lasting change: everylifefoundation.org/rare-advocates….

Join us in celebrating Amy Grover, our Executive Director of Patient Advocacy, who was recently recognized as a Rare Disease Day Hero! An honor that is truly well‑deserved. Amy was selected for her unwavering championing of patients and caregivers, making sure their needs are kept top of mind with our cross-functional teams that are working diligently to deliver our therapies. Amy’s commitment to patient advocacy was showcased in her leadership of our Catalyst Advocacy Scholars Summit (CASS), where she and her team mentored Notre Dame Med Students, inspiring a next generation of advocates. Learn more about her incredible work at Catalyst. mix-talent.com/rare-disease-d…

In honor of #RareDiseaseDay on February 28th, we are proud to support the Lambert‑Eaton LEMS Family Association, an organization that plays a vital role in educating, supporting, and empowering the 3,600 individuals and their families affected by Lambert‑Eaton myasthenic syndrome (LEMS). Their commitment to providing resources, building community, and advancing awareness makes a meaningful difference for those navigating this rare condition. Learn more about their work and how they advocate for the LEMS community: lemsfamily.org

Our scholars didn’t just attend sessions during our inaugural Catalyst Advocacy Scholars Summit (CASS); they stepped fully into the experience. From serving meals at the Ronald McDonald House to studying for capstones by the pool, they showed up with curiosity, commitment, and heart. Many are still in the midst of their studies, but CASS helped prepare them to lead with empathy, resilience, and purpose—wherever their paths take them next. They learned, they connected, and they never lost sight of the purpose behind this week: ensuring the voices of Duchenne and LEMS patients and families remain at the forefront of everything we do. We’re excited to see how they shape the future of advocacy: ir.catalystpharma.com/news-releases/… #CASS2026

Healthcare providers, Catalyst is at the @IASLC's 2026 Targeted Therapies of Lung Cancer Meeting. Learn more about our commitment to driving awareness for the early recognition of Cancer-Associated Lambert-Eaton myasthenic syndrome (CA-LEMS) by visiting us at the Catalyst table: cancerassociatedlems.com #TTLC26